416 related articles for article (PubMed ID: 25170594)
1. Short-term preseasonal immunotherapy: is early clinical efficacy related to the basophil response?
Kepil Özdemir S; Sin BA; Güloğlu D; İkincioğulları A; Gençtürk Z; Mısırlıgil Z
Int Arch Allergy Immunol; 2014; 164(3):237-45. PubMed ID: 25170594
[TBL] [Abstract][Full Text] [Related]
2. Allergen-induced basophil CD203c expression as a biomarker for rush immunotherapy in patients with Japanese cedar pollinosis.
Nagao M; Hiraguchi Y; Hosoki K; Tokuda R; Usui T; Masuda S; Yamaguchi M; Fujisawa T
Int Arch Allergy Immunol; 2008; 146 Suppl 1():47-53. PubMed ID: 18504407
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy with a modified birch pollen extract in allergic rhinoconjunctivitis: clinical and immunological effects.
Ceuppens JL; Bullens D; Kleinjans H; van der Werf J;
Clin Exp Allergy; 2009 Dec; 39(12):1903-9. PubMed ID: 20085600
[TBL] [Abstract][Full Text] [Related]
4. Desensitization effect of preseasonal seven-injection allergoid immunotherapy with olive pollen on basophil activation: the efficacy of olive pollen-specific preseasonal allergoid immunotherapy on basophils.
Gokmen NM; Ersoy R; Gulbahar O; Ardeniz O; Sin A; Unsel M; Kokuludag A
Int Arch Allergy Immunol; 2012; 159(1):75-82. PubMed ID: 22572984
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
Rossi RE; Monasterolo G
Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.
Schmid JM; Würtzen PA; Dahl R; Hoffmann HJ
J Allergy Clin Immunol; 2016 Feb; 137(2):562-70. PubMed ID: 26141262
[TBL] [Abstract][Full Text] [Related]
7. The effects of grass pollen allergoid immunotherapy on clinical and immunological parameters in children with allergic rhinitis.
Keskin O; Tuncer A; Adalioglu G; Sekerel BE; Saçkesen C; Kalayci O
Pediatr Allergy Immunol; 2006 Sep; 17(6):396-407. PubMed ID: 16925684
[TBL] [Abstract][Full Text] [Related]
8. Immunologic effects and tolerability profile of in-season initiation of a standardized-quality grass allergy immunotherapy tablet: a phase III, multicenter, randomized, double-blind, placebo-controlled trial in adults with grass pollen-induced rhinoconjunctivitis.
Reich K; Gessner C; Kroker A; Schwab JA; Pohl W; Villesen H; Wüstenberg E; Emminger W
Clin Ther; 2011 Jul; 33(7):828-40. PubMed ID: 21741092
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid.
Corrigan CJ; Kettner J; Doemer C; Cromwell O; Narkus A;
Allergy; 2005 Jun; 60(6):801-7. PubMed ID: 15876311
[TBL] [Abstract][Full Text] [Related]
10. Intradermal Phleum pratense allergoid immunotherapy. Double-blind, randomized, placebo-controlled trial.
Sola Martínez FJ; Barranco Jiménez RM; Martín García C; Senent Sánchez C; Blanco Guerra C; Fernández-Rivas M; Vega Castro A; Dávila González I; Carbonell Martínez A; Panizo Bravo C; Gómez Torrijos E; Rodríguez Gil D; Palacios Peláez R
Clin Exp Allergy; 2020 Dec; 50(12):1352-1361. PubMed ID: 32946612
[TBL] [Abstract][Full Text] [Related]
11. Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a 6-grass pollen allergoid.
Pfaar O; Hohlfeld JM; Al-Kadah B; Hauswald B; Homey B; Hunzelmann N; Schliemann S; Velling P; Worm M; Klimek L
Clin Exp Allergy; 2017 Nov; 47(11):1445-1455. PubMed ID: 28696503
[TBL] [Abstract][Full Text] [Related]
12. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy.
Pfaar O; Urry Z; Robinson DS; Sager A; Richards D; Hawrylowicz CM; Bräutigam M; Klimek L
Allergy; 2012 Feb; 67(2):272-9. PubMed ID: 22107266
[TBL] [Abstract][Full Text] [Related]
13. Sustained effect of grass pollen subcutaneous immunotherapy on suppression of allergen-specific basophil response; a real-life, nonrandomized controlled study.
Zidarn M; Košnik M; Šilar M; Bajrović N; Korošec P
Allergy; 2015 May; 70(5):547-55. PubMed ID: 25627309
[TBL] [Abstract][Full Text] [Related]
14. Intradermal grass pollen immunotherapy increases T
Slovick A; Douiri A; Muir R; Guerra A; Tsioulos K; Hay E; Lam EPS; Kelly J; Peacock JL; Ying S; Shamji MH; Cousins DJ; Durham SR; Till SJ
J Allergy Clin Immunol; 2017 Jun; 139(6):1830-1839.e13. PubMed ID: 27773851
[TBL] [Abstract][Full Text] [Related]
15. The Impact on Allergy-Related Cells of a Birch Pollen Allergoid, with and without Monophosphoryl Lipid A, in Comparison with the Native Equivalent.
Worm M; Ernst D; Kraller M; Babina M
Int Arch Allergy Immunol; 2017; 172(1):20-26. PubMed ID: 28219062
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy with a Phleum pratense allergen extract induces an immune response to a grass-mix allergen extract.
Martínez-Cócera C; Sastre J; Cimarra M; Quirce S; Fernández-Rivas M; Enríquez-Matas A; Rodríguez-Alvarez M; Martín S
J Investig Allergol Clin Immunol; 2010; 20(1):13-9. PubMed ID: 20232769
[TBL] [Abstract][Full Text] [Related]
17. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy.
Van Overtvelt L; Baron-Bodo V; Horiot S; Moussu H; Ricarte C; Horak F; Zieglmayer P; Zieglmayer R; Montagut A; Galvain S; de Beaumont O; Le Gall M; Moingeon P
Allergy; 2011 Dec; 66(12):1530-7. PubMed ID: 21883279
[TBL] [Abstract][Full Text] [Related]
18. Recombinant allergen-based monitoring of antibody responses during injection grass pollen immunotherapy and after 5 years of discontinuation.
Gadermaier E; Staikuniene J; Scheiblhofer S; Thalhamer J; Kundi M; Westritschnig K; Swoboda I; Flicker S; Valenta R
Allergy; 2011 Sep; 66(9):1174-82. PubMed ID: 21480924
[TBL] [Abstract][Full Text] [Related]
19. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
Klimek L; Schendzielorz P; Pinol R; Pfaar O
Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
[TBL] [Abstract][Full Text] [Related]
20. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
Rossi RE; Monasterolo G; Coco G; Operti D
Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
